MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive

Merck (MRK) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its 21-valent pneumococcal conjugate vaccine (PCV), Capvaxive, for the prevention of invasive pneumococcal disease (“IPD”) and pneumococcal pneumonia in individuals aged 18 years and above.The European Commission will now review the CHMP’s opinion and a final decision from the regulatory body is expected by the second quarter of 2025.The FDA approved Capvaxiv ...